Article Details

NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist ...

Retrieved on: 2021-08-23 12:00:00

Tags for this article:

Click the tags to see associated articles and topics

NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist .... View article details on hiswai:

Excerpt

By inhibiting ILT3's interaction with fibronectin, NGM831 represents another potential approach to mobilize a patient's own immune system to fight tumors by ...

Article found on: www.bakersfield.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up